Dr. Nathan Hayes: Maya, you sent me that setup last night and I haven't been able to let it go — the 30-year-old and the 75-year-old.
Maya Chen: Oh good, it got under your skin too.
Dr. Nathan Hayes: The mechanism is the same — both suppressing mTOR, mechanistic target of rapamycin, the kinase that drives anabolic growth and cell proliferation — but the clinical logic runs in opposite directions. That's genuinely strange.
Maya Chen: What I want to sit with is what that actually looks like in a body. The 30-year-old is fasting — skipping a meal, letting mTOR drop naturally. The 75-year-old has a rapamycin bottle on their nightstand, off-label, because someone in longevity medicine handed it to them.
Dr. Nathan Hayes: And rapamycin was discovered — the 50th anniversary of that discovery was just marked in a 2025 review — specifically because of what it does to mTOR. Five decades of research and we still can't say with confidence that a human taking it chronically is the same as a mouse living longer on it.
Maya Chen: Wait, that's the gap I want to understand — same pathway, but the age of the person changes everything about whether this is a gift or a liability.
Dr. Nathan Hayes: So the question is: when does mTOR suppression become the wrong medicine?
Maya Chen: That's it. That's exactly the thing we're trying to work out.
Dr. Nathan Hayes: Before we can answer that — I want to back up one layer, because the 'when' question only makes sense if you understand why these two systems can't just coexist. Think of it like a building. You've got a foreman who shows up the moment food arrives and says 'everyone build — protein synthesis, new cells, ribosomes.' That's mTOR. And you've got a maintenance crew that only gets called when the building stops. That's the other system. And here's the part that's actually structural — they cannot both run the site at once. That's not a metaphor. That's the architecture.
Maya Chen: Wait — why not, though? Why can't you just run both crews?
Dr. Nathan Hayes: One door. Literally one molecular door — it's called ULK1. The maintenance crew activates ULK1 to start the repair process, autophagy. The foreman phosphorylates that same ULK1 and blocks it. Same switch, opposite hands. Only one crew walks through at a time.
Maya Chen: So — mm — the cell is physically incapable of building and cleaning up simultaneously.
Dr. Nathan Hayes: Incapable. Now — the foreman, mTOR, flips on when amino acids like leucine and arginine show up. Food arrives, the signal fires, you build. The maintenance crew, AMPK, activates when your ATP drops and AMP rises — fasting, hard exercise, caloric restriction. And importantly, they're not just separate systems that happen to conflict. Michael N. Hall at the University of Basel — the researcher who mapped a lot of this foundational biology — the early 2000s work coming out of his lab and others showed AMPK and mTORC1 communicate through direct phosphorylation events. AMPK hits TSC2 and Raptor to shut mTOR down. mTOR suppresses AMPK in return. It's a mutual veto, built into the wiring.
Maya Chen: A mutual veto — that's the thing I didn't fully have. It's not just that one is quiet when the other is loud. They're actively silencing each other.
Dr. Nathan Hayes: Right — and that's what makes the 30-year-old fasting versus the 75-year-old on rapamycin such different stories. The 30-year-old is cycling. mTOR dominates at lunch, AMPK gets called in overnight. The veto goes back and forth. The 75-year-old who's been eating continuously — or the one who chemically suppresses mTOR without the metabolic shift — the maintenance crew either never gets summoned, or it's summoned artificially without the cell actually being in an energy-depleted state. And those are, mechanistically, not the same thing.
Maya Chen: Hmm. So the cycling is the point — not which system wins.
Dr. Nathan Hayes: The repair machinery, what we'd call autophagy — it atrophies when it's never called. And the build crew causes damage when it never stops. The 'when does this become wrong medicine' question you raised? I think the answer lives in the rhythm, not the direction.
Maya Chen: And the rhythm — that's where I think the evolutionary piece actually hits hardest. Because in an ancestral environment, you didn't schedule the repair window. Scarcity scheduled it for you. You went without food, AMPK came online, the cleanup crew arrived. That wasn't a wellness practice — it was just Tuesday.
Dr. Nathan Hayes: The fasting window was structural. Built into the food supply.
Maya Chen: Right — and now it's gone. Not because something broke in us, but because we removed the condition that made it automatic. Continuous eating means mTOR never fully steps back. The maintenance crew — autophagy, lysosomal recycling — it just... never gets the call. Damaged proteins accumulate, old organelles sit there. The cleanup crew doesn't show up because the foreman never left the site.
Dr. Nathan Hayes: And the damage doesn't announce itself. That's the actually unsettling part.
Maya Chen: Which — okay, here's where the age-dependence thing becomes almost cruel. Because at 25, chronic mTOR dominance isn't really chronic in the pathological sense — your muscle development, your immune response, wound healing, all of it needs mTOR firing. But at 55, that same signal is still running the same program, and the cell is accumulating garbage it was supposed to clear thirty years ago.
Dr. Nathan Hayes: The architecture that built you starts hoarding junk. Same signal, different consequence.
Maya Chen: There was a six-month randomized controlled trial — middle-aged adults, overweight, intermittent fasting protocol — and the numbers were actually striking. Eight percent body weight reduction, sixteen percent decrease in body fat, and metabolomic and transcriptomic shifts in exactly the pathways we're describing. mTOR and AMPK relevant signaling. That's not animal data. That's the repair window being restored in people who just changed when they ate. And LKB1 — the upstream kinase that activates AMPK, which Reuben Shaw at the Salk Institute was central in mapping — that's the switch being flipped every single time that window opens.
Dr. Nathan Hayes: Sixteen percent body fat reduction in six months — that's not trivial. That's a population-level signal.
Maya Chen: And then — I mean, this is where I want to go next, because it gets complicated fast — we have rapamycin doing this pharmacologically in mice, and metformin positioned as the human candidate. But whether the evidence actually supports that leap from animal model to 'take this drug'... that's the part I think we haven't fully reckoned with yet.
Dr. Nathan Hayes: And that leap — rapamycin to humans — is exactly where I have to pump the brakes hard. The mouse data is real. Multiple animal models, robust lifespan extension, fifty years of work. But a mouse on rapamycin is not a 70-year-old with comorbidities taking it off-label. Immunosuppression in a mouse is not — I mean, the stakes are just categorically different. Wound healing impaired, infection risk elevated. The anti-aging narrative tends to flatten that into a footnote.
Maya Chen: Not a footnote if you get sepsis.
Dr. Nathan Hayes: Correct. And the long-term safety data in healthy humans simply does not exist yet. People are taking it anyway — off-label, growing numbers in longevity medicine — but that's a social trend, not a clinical recommendation.
Maya Chen: Which brings me to metformin, because we've positioned it as the human candidate because it activates AMPK. But what if that's not actually the primary mechanism?
Dr. Nathan Hayes: Wait — say more.
Maya Chen: The research hints that metformin's benefits may come through other pathways — not primarily AMPK activation. If we've built an entire 'activate AMPK to live longer' story, and the drug we're pointing to as evidence actually works through something else... doesn't the whole frame need reexamining?
Dr. Nathan Hayes: That's — yeah, that genuinely unsettles the clean version. And metformin's evidence in non-diabetic humans for actual lifespan extension is still incomplete. It's the most-studied candidate we have, but 'most-studied' and 'proven' are not the same sentence.
Maya Chen: So what does hold up? If rapamycin is too risky to recommend and metformin's mechanism is murkier than we thought —
Dr. Nathan Hayes: Exercise. Actually, no — specifically what exercise does to the cycling. It transiently activates AMPK during effort, then permits mTOR to come back online during recovery. You're not chronically suppressing either pathway. You're enforcing the rhythm the system actually requires. That's the intervention that's clean — not because it's boring, but because the mechanism is exactly right.
Maya Chen: The rhythm. That's this image of a biological clock. Not the kind that counts down, but the kind that cycles. And what scares me isn't that the clock stops eventually. It's that it might stop cycling long before that, while you're still completely functional, and there's no readout. Nothing tells you the repair window has quietly closed.
Dr. Nathan Hayes: Can we even measure that in a living person right now? The cycling itself — not a proxy, not a metabolomic snapshot, but the actual rhythm of mTOR and AMPK shifting between states in real time?
Maya Chen: That's what I don't think we can do yet.
Dr. Nathan Hayes: No. We can't. And honestly — that's the question the next decade of research has to answer.
Maya Chen: I'm glad we didn't pretend otherwise.
